OBJECTIVE: To evaluate the repeatability of gallium-68 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic (DOTA)-D-Phe1-Try3-octreotide (68Ga-DOTATOC) positron emission tomography (PET) in neuroendocrine tumors. METHODS: Five patients with neuroendocrine tumors were imaged with 68Ga-DOTATOC PET twice within 5 days. Maximum and mean standardized uptake values (SUVmax and SUVmean) and kinetic parameters (K-Patlak and K-influx) of target lesions were measured. The repeatability of these measurements was investigated. RESULTS: Forty-seven target lesions were identified on whole-body PET and 21 lesions on dynamic images. There was excellent repeatability with intraclass correlation coefficient of 0.99 for SUVmax, SUVmean, and K-Patlak, and 0.85 for K-influx. The median absolute percent differences and the interquartile ranges (IQR) between 2 scans for SUVmax and SUVmean were 7.4% (IQR, 14.1%) and 9.3% (IQR, 10.6%), respectively. The median absolute percent differences for K-Patlak and K-influx were 12.5% (IQR, 12.6%) and 29.9% (IQR, 22.4%), respectively. The SUVmax of target lesions did not differ by more than 25% between the 2 scans. CONCLUSIONS: 68Ga-DOTATOC PET imaging of neuroendocrine tumors is highly reproducible. A difference of more than 25% in SUVmax represents a change that is larger than the measurement error observed on repeated studies and should reflect a significant change in the biological character of the tumor.
OBJECTIVE: To evaluate the repeatability of gallium-68 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic (DOTA)-D-Phe1-Try3-octreotide (68Ga-DOTATOC) positron emission tomography (PET) in neuroendocrine tumors. METHODS: Five patients with neuroendocrine tumors were imaged with 68Ga-DOTATOC PET twice within 5 days. Maximum and mean standardized uptake values (SUVmax and SUVmean) and kinetic parameters (K-Patlak and K-influx) of target lesions were measured. The repeatability of these measurements was investigated. RESULTS: Forty-seven target lesions were identified on whole-body PET and 21 lesions on dynamic images. There was excellent repeatability with intraclass correlation coefficient of 0.99 for SUVmax, SUVmean, and K-Patlak, and 0.85 for K-influx. The median absolute percent differences and the interquartile ranges (IQR) between 2 scans for SUVmax and SUVmean were 7.4% (IQR, 14.1%) and 9.3% (IQR, 10.6%), respectively. The median absolute percent differences for K-Patlak and K-influx were 12.5% (IQR, 12.6%) and 29.9% (IQR, 22.4%), respectively. The SUVmax of target lesions did not differ by more than 25% between the 2 scans. CONCLUSIONS: 68Ga-DOTATOC PET imaging of neuroendocrine tumors is highly reproducible. A difference of more than 25% in SUVmax represents a change that is larger than the measurement error observed on repeated studies and should reflect a significant change in the biological character of the tumor.
Authors: Thorsten D Poeppel; Ina Binse; Stephan Petersenn; Harald Lahner; Matthias Schott; Gerald Antoch; Wolfgang Brandau; Andreas Bockisch; Christian Boy Journal: J Nucl Med Date: 2011-11-09 Impact factor: 10.057
Authors: Helena R Balon; Tracy L Y Brown; Stanley J Goldsmith; Edward B Silberstein; Eric P Krenning; Otto Lang; Gary Dillehay; Jennifer Tarrance; Matt Johnson; Michael G Stabin Journal: J Nucl Med Technol Date: 2011-11-08
Authors: Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2010-10 Impact factor: 9.236
Authors: Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Linda M Velasquez; Ronald Boellaard; Georgia Kollia; Wendy Hayes; Otto S Hoekstra; Adriaan A Lammertsma; Susan M Galbraith Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: Wouter A P Breeman; Erik de Blois; Ho Sze Chan; Mark Konijnenberg; Dik J Kwekkeboom; Eric P Krenning Journal: Semin Nucl Med Date: 2011-07 Impact factor: 4.446
Authors: Michael Gabriel; Andreas Oberauer; Georg Dobrozemsky; Clemens Decristoforo; Daniel Putzer; Dorota Kendler; Christian Uprimny; Peter Kovacs; Reto Bale; Irene J Virgolini Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: H Hartmann; K Zöphel; R Freudenberg; L Oehme; M Andreeff; G Wunderlich; G Eisenhofer; J Kotzerke Journal: Nuklearmedizin Date: 2009-07-28 Impact factor: 1.379
Authors: Yusuf Menda; Thomas M O'Dorisio; James R Howe; Michael Schultz; Joseph S Dillon; David Dick; G Leonard Watkins; Timothy Ginader; David L Bushnell; John J Sunderland; Gideon K D Zamba; Michael Graham; M Sue O'Dorisio Journal: J Nucl Med Date: 2017-02-02 Impact factor: 10.057
Authors: Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-29 Impact factor: 9.236
Authors: Dirk Mueller; Wouter A P Breeman; Ingo Klette; Michael Gottschaldt; Andreas Odparlik; Manfred Baehre; Izabela Tworowska; Michael K Schultz Journal: Nat Protoc Date: 2016-05-12 Impact factor: 13.491
Authors: Julie Refardt; Maria J Klomp; Peter M van Koetsveld; Fadime Dogan; Mark Konijnenberg; Tessa Brabander; Richard A Feelders; Wouter W de Herder; Leo J Hofland; Johannes Hofland Journal: Clin Transl Med Date: 2022-07
Authors: Janet H Pollard; Yusuf Menda; K D Zamba; Mark Madsen; M Sue O'Dorisio; Thomas O'Dorisio; David Bushnell Journal: Cancer Biother Radiopharm Date: 2021-07-12 Impact factor: 3.632